Clinical Trial Update: PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan

View source ↗

Summary

An observational registry update (PULSE Registry) for patients receiving lutetium-177 vipivotide tetraxetan in metastatic prostate cancer; recruitment not yet s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Prostate Cancer | Status: NOT_YET_RECRUITING